Denali Therapeutics Inc. (DNLI)

Denali Therapeutics, headquartered in South San Francisco, California, is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS. Led by CEO Ryan Watts, the company’s strategy is "The Blood-Brain Barrier (BBB) Specialist"—utilizing its proprietary "Transport Vehicle" (TV) technology to deliver therapeutics across the BBB more effectively. Its core strategy centers on "Strategic Partnerships" with Biogen and Takeda and its "DNL310" program for Hunter syndrome. Denali’s mission is to defeat neurodegeneration. The company is currently a high-value biotech player, utilizing its unique platform and robust cash position to lead the next generation of precision medicine for the brain.